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Abstract
All pharmaceutical companies are required to assess pharmacokinetic drug-drug interac-
tions (DDIs) of new chemical entities (NCEs) and mathematical prediction helps to select
the best NCE candidate with regard to adverse effects resulting from a DDI before any costly
clinical studies. Most current models assume that the liver is a homogeneous organ where
the majority of the metabolism occurs. However, the circulatory system of the liver has a
complex hierarchical geometry which distributes xenobiotics throughout the organ. Never-
theless, the lobule (liver unit), located at the end of each branch, is composed of many
sinusoids where the blood flow can vary and therefore creates heterogeneity (e.g. drug con-
centration, enzyme level). A liver model was constructed by describing the geometry of a
lobule, where the blood velocity increases toward the central vein, and by modeling the
exchange mechanisms between the blood and hepatocytes. Moreover, the three major DDI
mechanisms of metabolic enzymes; competitive inhibition, mechanism based inhibition and
induction, were accounted for with an undefined number of drugs and/or enzymes. The liver
model was incorporated into a physiological-based pharmacokinetic (PBPK) model and sim-
ulations produced, that in turn were compared to ten clinical results. The liver model gener-
ated a hierarchy of 5 sinusoidal levels and estimated a blood volume of 283 mL and a cell
density of 193 × 106 cells/g in the liver. The overall PBPK model predicted the pharmacoki-
netics of midazolam and the magnitude of the clinical DDI with perpetrator drug(s) including
spatial and temporal enzyme levels changes. The model presented herein may reduce
costs and the use of laboratory animals and give the opportunity to explore different clinical
scenarios, which reduce the risk of adverse events, prior to costly human clinical studies.
Introduction
A pharmacokinetic drug-drug interaction (DDI) is where a drug(s), the perpetrator drug(s),
interacts with a metabolizing enzyme(s) or membrane transporter(s) such that the
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pharmacokinetics (PK) of another drug(s), the victim drug(s), is altered. In the late 1970s, the
first cases of pharmacokinetic DDIs were reported [1], and since then more and more DDIs
have been identified especially in the situation of polypharmacy as is often the case for elderly
patients [2]. The increase in observed DDIs coupled to some lethal cases [1] led the FDA to
publish in 1997 the first in vitro metabolism drug interaction guidance document [3] for phar-
maceutical companies. In order to identify the possible interactions of new chemical entities
(NCEs), many strategies have been suggested as it is essential to know before costly clinical tri-
als, whether a NCE will be a safe drug. One of those strategies relies on the combination of in
vitro information coupled to mathematical models to predict the clinical DDIs. This has the
advantage to be cost effective, reduce the use of laboratory animals and give the opportunity to
explore different clinical scenarios in order to identify optimum dose regimens. Excluding the
limitations of in vitro experiments, the modeling approach is limited by the sophistication of
the implemented models. Current models are classified into two different categories that
depend on whether they are a function of time or not (i.e. static and dynamic models), and
mainly focus on one enzyme and/or one particular aspect of DDIs (e.g. reversible inhibition
[4], mechanism based inhibition [5] or induction [6]). In their most advanced form the static
models may account for all kinds of DDIs [7], but are limited in their ability to describe com-
plex mechanisms related to administration, distribution, metabolism or excretion such as
active drug transport (uptake) into hepatocytes or enterocytes. Although the dynamic models
are more descriptive, traditionally, the dynamic models were developed to describe specific
drug cases [4, 5, 8] and most of them assume that the liver is a homogeneous organ (e.g. well-
stirred model [9, 10]) where the majority of the metabolism occurs. However, the circulatory
system of the liver has a complex hierarchical geometry which helps to distribute xenobiotics
throughout the organ. Nevertheless, the lobule (liver unit), located at the end of each branch, is
composed of many sinusoids (small blood vessels) where the blood flow can vary and therefore
creates heterogeneity (e.g. drug concentration, enzyme level). Some liver models account for
heterogeneity, such as the parallel tube model [9, 10] and the dispersion model [11, 12], but
they have not been used to predict DDIs and do not account for the variation in blood flow
through the lobules. With established methodologies of in vitro screening for DDIs, pharma-
ceutical companies need adequate tools to predict the net result of in vivo DDIs to translate
their in vitro observations to clinical predictions. It is common for elderly patients to receive
several medications to treat different symptoms or conditions. Each of these medicines can
potentially interfere with the usual routes of metabolism for another drug. There is a serious
need for better models to cover all different scenarios, which also takes into account the vari-
abilities between individuals, such as size, weight and differences in genetic polymorphisms
[13]. In this paper, a liver model will be presented that takes into account three major DDI
mechanisms of metabolic enzymes; competitive inhibition, mechanism based inhibition
(MBI) and induction, with an undefined number of drugs and/or enzymes, where the lobule
geometry will be accounted for due to its impact on blood flow heterogeneity. The liver model
will then be incorporated into a physiological-based pharmacokinetic (PBPK) model and sim-
ulations produced that in turn will be compared to clinical results. The description of the
model proposed herein is divided into six parts. The first part will introduce the model and the
notations used throughout the document including a new liver model taking into consider-
ation its hierarchical structure and the different body compartments that are essential to drug
metabolism. In the second part, the algorithm to generate the lobule geometry will be pre-
sented, where length and radius of the sinusoids are produced. In the third part, the transport
and metabolism reactions of the drugs will be mathematically described. As the drugs are dis-
tributed in the body through the bloodstream, the conservation equation will be used in the
liver sinusoids to describe the blood transport and the exchange mechanisms between the
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blood and hepatocytes, such as passive diffusion and active uptake/efflux of the drugs. Inside
the hepatocytes, drug metabolism and drug interactions with metabolic enzymes will be
described. In the fourth part, the PBPK model presented in part one will be fully developed. In
part five, a brief description on how the PBPK was numerically resolved will be given. In the
sixth part, drugs for which data exist will be considered and their physiological parameters
defined. Finally the results from the new liver model will be presented and compared to clinical
data.
Models
Presentation of the liver model and notations
The objective of this section is to provide a brief explanation of the subsequent models that
will be used to develop a formal understanding of DDIs. There are three major aspects to con-
sider; (i) the geometry of the lobule (ii) the set of complex interactions between xenobiotics
and enzymes (iii) the usual set of body compartments (PBPK Model).
Drugs move with the flow of blood and as a result the exchange mechanisms of drug
between the blood and the tissue will be a function of the lobule geometry in which the flow
takes place. The lobules have a peculiar shape idealized as hexagons composed of a series of
peripheral entries (portal veins and hepatic arteries) and a central vein (Fig 1A and 1B). This
spatial configuration and its hierarchical structure will need to be taken into consideration in
order to describe the blood flow and to generate an algorithm to construct a lobule within the
physiological constraints. Furthermore, the blood velocity will be assumed constant and aver-
aged over the cross section of sinusoids present within the lobule while it will vary along the
length of sinusoids as their radii narrow. The latter assumption is the only one that will be
used, which reduces the spatial dimension to one. The spatial variable is noted x and for each
sinusoids portion the x-axis is taken along the bisector and goes from the external part of the
lobule to the central vein (Fig 1C).
To describe the DDIs no assumptions will be made on the number of drugs and enzymes
involved to make the model generic for all animal species. However, the only way to achieve
this is to consider matrix calculus. While this may appear as an unnecessary complication at
first sight, it will be seen that with adequately defined operators the writing of equations is
largely intuitive even for those not fully familiar with matrix algebra. To start with, the follow-
ing notations nC and nE will refer to the number of drugs and enzymes, respectively. To distin-
guish between scalars and matrices (including vectors), matrices and vectors are written in
bold. Thus any set of variables or constants related to drugs shall be described as a column vec-
tor of size nC including their concentrations: C = (C1  CnC)
tr or membrane permeability:
P = (P1  PnC)
tr. Note here that the subscript “tr” refers to the transposition of a column vector
into a vector line (the same notation shall be used for matrices where in this case the operator
transposed is noted: Atr ¼ ðatri;jÞ 1  i  m
1  j  n
¼ ðaj;iÞ 1  i  m
1  j  n
where A ¼ ðai;jÞ 1  i  n
1  j  m
). Similarly, any
set of variables or constants related to enzymes or their degradation shall be described as a col-
umn vector of size nE including for example the enzyme concentrations: E = (E1  EnE)
tr; or
their degradation: kdeg = (kdeg, 1  kdeg, nE)
tr. As the number of possible pair interactions
between enzymes and drugs is given by the scalar product: nC × nE, one defines the matrix
EC ¼ ðECi;jÞ 1  i  nC
1  j  nE
where the term ECi, j represents the interaction of the i-th drug with the
j-th enzyme. Finally, as the interaction between the i-th drug with the j-th enzyme can lead to
the formation of a product one needs to specify the kinetics of the reaction by another parame-
ter, kcat, i, j, specific to the ECi, j complex. In these conditions the scalar product kcat, i, j × ECi, j
A quantitative systems pharmacology model to predict pharmacokinetic drug-drug interactions
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Fig 1. Lobule geometry and modelling. (A) The lobule cross section as represented displays an apparent elementary
symmetry essential for its physiology primarily given by the blood vessels and the blood flow (Credit to Dr. Roger C. Wagner,
University of Delaware). (B) This symmetry is used when lobule modeling or representation are involved. In general, a lobule is
represented by a hexagon composed of hepatocyte plates. These plates are hierarchically organized to optimize exchanges.
(C) To model the blood flow (and subsequent exchanges between the liver tissues and the blood), an algorithm was designed to
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define the reaction rate of the reaction. To use matrices one needs to define the following oper-
ators: “” such that kcat  EC ¼ ðkcat;i;j  ECi;jÞ 1  i  nC
1  j  nE
. By extension, a division operator is
defined and noted “/” or “−” between vectors or matrices such that: x=y ¼ xy ¼
xi;j
yi;j
 
1  i  n
1  j  m
.
Finally for completion the column vectors of size nC or nE and of components equal to unity
shall be noted: 1nC and 1nE .
Last but not least, a seven-compartment model is used involving: venous blood, arterial
blood, liver, gut, kidneys, lungs (to consider the pulmonary circulation), and the rest of the
body (Fig 2). The average volume and blood flow of each compartment is given in S1 Table.
Lobule geometry
The lobule is the elementary unit of the liver where the exchange of nutrients and xenobiotic
compounds occurs between the blood and the hepatocytes. The shape of the lobule and the
spatial distribution of the hepatocytes are irregular in appearance (Fig 1A). But schematically,
the liver lobule can be represented by a hexagon (Fig 1B), where the hepatic vein is at the cen-
tre and where at each apex, the hepatic artery and the hepatic portal vein pour blood into the
sinusoids. The sinusoids are converging toward the centre where the blood leaves the lobule
through the central vein (Fig 1B).
To suggest a theory on which an amenable model will be based, the lobule geometry will be
simplified. The parameters used to define the geometry are summarized in Table 1, whereas
the algorithm to build the lobule geometry for the simulations is schematically represented in
Fig 1C where each step is numbered and detailed as below:
1. The hexagonal shape of the lobule is replaced by a disc of similar area: 3
ffiffi
3
p
2
R2lobule ¼ pR
2
Circle.
2. Due to the symmetry of an hexagon, only one sixth of the circle will be taken into account.
3. The initial two hepatocyte plates are placed on either edge of the sector (one sixth of the cir-
cle) and respect a minimal distance of 2RSin between the hepatocytes plates, the initial dis-
tances from the centre are estimated by:
a. The first sinusoid output: x0 ¼
RSin
tan y1 þ
e
2 sin y1
where yk ¼
y0
2k
and θ0 = 60˚.
b. The first hepatocyte plate: y0 ¼
RSin
sin y1
þ e
2 tan y1.
c. Iteration initialization: k = 0
4. A loop is implemented as follow: while xk RCircle do
a. k = k + 1
b. Place a hepatocyte plate on each line of angle θk + (i − 1)θk − 1 for 8i 2 {1, . . ., 2k − 1},
such as the minimal distance of the new hepatocyte plate to the previous one is 2RSin cos
θk + 1, which gives an output diameter of 2RSin.
c. The distance of the outputs: xk ¼
RSin
tan ykþ1 þ
e
2 sin ykþ1
.
automatically generate the length and radius of the sinusoids. The latter is used to estimate the changes in velocity within a
sinusoid portion by assuming a constant blood flow and a constant velocity over the cross section.
https://doi.org/10.1371/journal.pone.0183794.g001
A quantitative systems pharmacology model to predict pharmacokinetic drug-drug interactions
PLOS ONE | https://doi.org/10.1371/journal.pone.0183794 September 14, 2017 5 / 28
Fig 2. The seven compartmental model. Red and blue arrows represent blood flows (Qi where i represents: T for total blood flow, ha
hepatic artery blood flow, pv portal vein blood flow, L for the liver blood flow, G for the gut blood flow, K for the kidneys blood flow and RB for
the blood flow going to the rest of the body). The black arrows represent absorption (ka: absorption constant rate) or excretion (CLR: Renal
Clearance).
https://doi.org/10.1371/journal.pone.0183794.g002
A quantitative systems pharmacology model to predict pharmacokinetic drug-drug interactions
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d. The distance of the new plates: yk ¼
RSin
sin ykþ1
þ e
2 tan ykþ1.
5. When xk  RCircle the last level of sinusoid is reached and one poses n = k. Then in order to
be consistent with the direction of the blood flow, the level 1 is defined as the furthest level
from the central vein, and the level n as the closest one.
6. As a result, the length of each sinusoids level is given by: Lk = min(yn− k+1, RCircle) − xn − k.
Now that the number and the length of the sinusoid levels are defined, the radius within
each level changes which is expected to impact the exchange of chemicals between the blood
and the hepatocytes. Therefore it is essential to calculate the sinusoid radius changes for every
level defined above. The radius along the sinusoids of level k, following the blood flow, is then
given by:
RkðxÞ ¼ RSin þ ðLk   xÞ tanyn  kþ1 8x 2 ½0 : Lk ð1Þ
Finally, as one assumes that the blood flow Qk at a given level k is identical for all sinusoids,
the blood flow and the average velocity are given by:
Qk ¼
QLobule
6  2n  k
vkðxÞ ¼
Qk
pRkðxÞ
2
8x 2 ½0 : Lk
8
>
<
>
:
ð2Þ
where the flow in a lobule is QLobule = QLiver/NLobule with NLobule = VLiver/VLobule and VLiver and
VLobule are, respectively, the liver and lobule volumes. This assumes the same flow in each lob-
ule. Finally, to simplify the notation, in the remaining text we define:
8x 2 ½0 : Ln
RðxÞ ¼ R1ðxÞ1½L0:L1  þ
Xn
k¼2
Rkðx   Lk  1ÞILk  1:LkðxÞ
QðxÞ ¼ Q1ðxÞ1½L0:L1  þ
Xn
k¼2
Qkðx   Lk  1ÞILk  1:LkðxÞ
vðxÞ ¼ v1ðxÞ1½L0:L1  þ
Xn
k¼2
vkðx   Lk  1ÞILk  1:Lk ðxÞ
8
>
>
>
>
>
><
>
>
>
>
>
>:
ð3Þ
where 8k 2〚1 : n〛Lk ¼ Lk  1 þ Lk, L0 ¼ 0 and IE is the indicator function of E.
Table 1. Lobule parameters.
Parameter Description Value
RLobule Lobule Radius 790.57μm [14]
Rsin Minimal Sinusoidal Radius 3.65μm [14]
eLobule Lobule Thickness 25.00μm [14]
RH Hepatocyte Radius 8.49μm [14]
e Hepatocyte Plate Width(= 2RH) 16.97μm
https://doi.org/10.1371/journal.pone.0183794.t001
A quantitative systems pharmacology model to predict pharmacokinetic drug-drug interactions
PLOS ONE | https://doi.org/10.1371/journal.pone.0183794 September 14, 2017 7 / 28
Conservation and kinetic equations for the liver model
Conservation equation in the blood. Now that the lobule geometry has been defined, the
equations which describe the transport and metabolism of drugs in the liver can be expressed.
Before being metabolized in the hepatocytes, the drugs flow with the blood through the lobules
and are passively or actively transported into the hepatocytes. Considering nC drugs and
assuming no irreversible reaction within the blood, the conservation equation can be used to
describe the concentrations such as:
@Cb
@t
þ v xð Þ
@Cb
@x
¼   aB!H xð Þ P þ ρinð Þ  f
b
u  Cb   P þ ρoutð Þ  f
h
u  Ch
 
ð4Þ
where Cb, Ch, P, ρin, ρout, f bu, f
h
u and v(x) are, respectively, the concentrations of the drugs in
the liver blood and hepatocytes, the permeability and the uptake/efflux rates through the
hepatocyte membrane, the fraction unbound in the blood and hepatocytes and the blood
velocity; and where αB! H(x) is the ratio of the elementary blood-hepatocyte surface exchange
δSExchange(x) to the elementary blood volume δVBlood(x) (see S1 Appendix), given by:
aB!H xð Þ ¼
2R xð Þ þ
eL   2RH
cosyðxÞ
RðxÞðeL   2RHÞ
ð5Þ
As the blood flow enters the sinusoid from the hepatic arteries at x = 0, the initial and bound-
ary conditions are given by:
Cbðx > 0; t ¼ 0Þ ¼ 0
Cbðx ¼ 0; tÞ ¼ C0ðtÞ
Chðx; t ¼ 0Þ ¼ 0
8
><
>:
ð6Þ
where C0(t) will be defined once the PBPK model will be decribed.
Drug kinetic equation in the hepatocytes. Once the drugs enter inside the hepatocytes
by passive and/or active transport, a cascade of reactions may occur involving metabolism of
the drugs by one or more enzymes and includes cross reaction(s) between metabolite(s) and
drug(s). The presented model focuses specifically on the reactions schematically represented
in Fig 3 (i.e. Competitive Inhibition, MBI and Induction).
Furthermore, it will be assumed that no exchange of materials between hepatocytes happens
and that the equilibrium between the drugs and enzyme complex is quickly reached (see S2
Appendix for the mathematical simplification). Therefore, by using the law of conservation of
mass, one can describe the equation governing the concentration of drugs within the hepato-
cytes by:
dCh
dt
¼ aH!BðxÞ½ðP þ ρinÞ  f
b
u  Cb   ðP þ ρoutÞ  f
h
u  Ch
  ðkcat  ECMetÞ1nE
  ðkinact  ECMBIÞ1nE
 
Vmax;2
Km;2 þ f
h
u  Ch
 f hu  Ch
ð7Þ
where ECMet ¼ ðECMet;i;jÞ 1  i  nC
1  j  nE
represents the concentration of complex involved in the
A quantitative systems pharmacology model to predict pharmacokinetic drug-drug interactions
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metabolism of drugs, ECMBI ¼ ðECMBI;i;jÞ 1  i  nC
1  j  nE
the concentration of complex inactivating the
enzymes and; Vmax, 2 and Km, 2 the constants associated with unspecified metabolic pathway
(s), modeled by a Michaelis-Menten equation. Finally αH! B(x) is the ratio of the elementary
blood-hepatocyte surface exchange δSExchange(x) to the elementary hepatocyte volume δVHep(x)
(see S1 Appendix), given by:
aH!B xð Þ ¼
2R xð Þ þ
eL   2RH
cosy
RH 2Rk xð Þ þ
eL
cosy
  ð8Þ
Eq (7) can be rewritten considering the rapidly attained equilibrium assumption. In this
context the enzyme-drug complex concentrations can be expressed as a function of the free
Fig 3. Enzymatic reactions taken into account in the liver model. Reversible inhibition: A drug binds to an enzyme which may result in
its metabolism (but not necessarily) resulting in the temporary blockade or inhibition of the enzyme. Here only competitive inhibition will be
studied, which assumes that each enzyme can interact with one drug at a time. Mechanism Based Inhibition (MBI): A drug inactivates an
enzyme through direct interaction resulting in an inhibited metabolism of any drug metabolized by these enzymes. Induction: A drug induces
the expression of one or more enzymes resulting in an induced metabolism of any drug metabolized by these enzymes. Note that the
notations in this figure regarding the kinetic rate constants are used in the text.
https://doi.org/10.1371/journal.pone.0183794.g003
A quantitative systems pharmacology model to predict pharmacokinetic drug-drug interactions
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enzyme levels and drug concentrations as follow:
ECMet ¼
ðf hu  ChÞE
tr
Km;1
ECMBI ¼
ðf hu  ChÞE
tr
KI
ð9Þ
where E = (E1, . . ., EnE)
tr represents the free enzyme levels and where the constants
Km;1 ¼
k21 þ kcat
k12
and KI ¼
k41 þ kinact
k14
are developed in S2 Appendix. Therefore the equation
becomes:
dCh
dt
¼ aHBðxÞ½ðP þ ρinÞ  f
b
u  Cb   ðP þ ρoutÞ  f
h
u  Ch
  kcat=Km;1 þ kinact=KI
  
E
 
 f hu  Ch  
Vmax;2
Km;2 þ f
h
u  Ch
 f hu  Ch
ð10Þ
Enzyme kinetic equation in the hepatocytes. The remaining set of equations needs to
describe the enzyme kinetics. In general the level of enzymes are assumed to be constant, but
when MBI and/or induction occur, changes in enzyme levels are not immediate and time
needs to be taken into consideration. Therefore modelling the enzyme kinetics is essential,
using classical kinetic equations and assuming that the enzyme induction is additive, the fol-
lowing can be written:
dETot
dt

dE
dt
¼ kdeg  E0 þ
Emax   1nCE
tr
0
EC50 þ ðf
h
u  ChÞ1
tr
nE
 !tr
ðf hu  ChÞ   ETot
" #
  ðkinact  ECMBIÞ
tr1nC
dECMet
dt
¼
dECInh
dt
¼
dECMBI
dt
 0
ETot ¼ E þ ½ECMet þ ECInh þ ECMBI
tr1nC
8
>
>
>
>
>
><
>
>
>
>
>
>:
ð11Þ
where ECInh ¼ ðECInh;i;jÞ 1  i  nC
1  j  nE
is the concentration(s) of complex that does not metabolize
the drugs and is also given by ECInh ¼
ðf hu  ChÞE
tr
Ki
where Ki ¼
k31
k13
(see S2 Appendix). The
equation above can be further simplified by using Eq (9) and by normalizing the enzyme levels
by its initial and basal level E0 and by noting ETot ¼ ETot=E0 and FImax ¼ Emax=ð1nCE0
trÞ:
dETot
dt
¼ kdeg  1þ
ðFImax   1Þ
EC50 þ ðf
h
u  ChÞ1
tr
nE
 !tr
ðf hu  ChÞ   ETot  1þ
1
kdeg

kinact
KI
 tr
ðf hu  ChÞ
1þ
1
Km;1
þ
1
Ki
þ
1
KI
 !tr
ðf hu  ChÞ
0
B
B
B
B
B
@
1
C
C
C
C
C
A
2
6
6
6
6
6
4
3
7
7
7
7
7
5
E ¼
ETot
1þ
1
Km;1
þ
1
Ki
þ
1
KI
 !tr
ðf hu  ChÞ
ð12Þ
8
>
>
>
>
>
>
><
>
>
>
>
>
>
>:
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Note that if a drug is not metabolized or does not bind or inactivate a specific enzyme, the
related constant is set to infinity, which corresponds to an infinite potency. Furthermore, it is
important to note that if two drugs are metabolized by the same enzyme site they automatically
inhibit each other and as a result Ki can be taken as infinity, except if it is suspected that two
binding sites are active for a given drug (e.g. one will metabolize the drug whereas the other
will just bind to it). However it is difficult to make this distinction experimentally.
PBPK model
Having the liver model defined and the related enzymatic reactions, they need to be incorpo-
rated into a PBPK model to be able to simulate the PK of the different drugs and predict their
interactions. As seen above, the PBPK model is constituted of 7 compartments: Arterial Blood,
Venous Blood, Liver, Gut, Kidneys, Lungs and the Rest of the Body (RB) (Fig 2). All compart-
ments, except the liver and gut, are modeled below as classical compartments associated with
their own physiological volume and partition coefficient for drugs [15]. Furthermore, as the
drug(s) is(are) administered orally at t = 0 the initial concentration of all compartments is
taken equal to zero. Finally, each of the compartments is defined as:
• Arterial Blood Compartment:
VAB
dCAB
dt
¼ QT
CLungs  RBP
Kp;Lungs
  CAB
 !
ð13Þ
where CAB and VAB are the concentration of drugs and volume of the arterial blood, QT the
total blood flow and CLungs and Kp, Lungs the concentration and partition coefficient of the
lungs; and RBP the blood-to-plasma ratio.
• Venous Blood Compartment:
VVB
dCVB
dt
¼ QLiverCLiver þ QK
CK  RBP
Kp;K
þ QRB
CRB  RBP
Kp;RB
  QTCVB ð14Þ
where CVB and VVB are the concentration of drugs and volume of the venous blood com-
partment, CLiver and QLiver are the concentration of drugs and blood flow for the liver and
where, CK, CRB, QK, QRB, Kp, K and Kp, RB, CLiver are the concentrations of drugs, the blood
flows and partition coefficients of the kidney and the compartment corresponding to the
rest of the body (RB-compartment), respectively. To be more specific CLiver is the concentra-
tion at the exit of the lobule.
• Kidney Compartment:
VK
dCK
dt
¼ QK CAB  
CK  RBP
Kp;K
 !
  CLint;R  CK ð15Þ
where CLint, R is the intrinsic renal clearance.
• Lung Compartment:
VLungs
dCLungs
dt
¼ QLungs CVB  
CLungs  RBP
Kp;Lungs
 !
ð16Þ
where VLungs and QLungs are the volume of the lungs and blood flow in the lungs,
respectively.
A quantitative systems pharmacology model to predict pharmacokinetic drug-drug interactions
PLOS ONE | https://doi.org/10.1371/journal.pone.0183794 September 14, 2017 11 / 28
• RB-Compartment:
VRB
dCRB
dt
¼ QRB CAB  
CRB  RBP
Kp;RB
 !
ð17Þ
• Gut Compartment:
The gut compartment is composed of two sub-compartments [16]; the gut wall and the por-
tal vein sub-compartments (Fig 4). The model to describe the gut wall sub-compartment is
similar to the liver model with a few differences including a homogeneous compartment
with a first order absorption, differences in enzyme levels and convection to the portal vein.
Therefore the concentration of drugs and enzymes within the gut wall are described by:
dCg
dt
¼
XnDose
i¼1
Fa  Di  ka
Vg
 expð  kaðt   TiÞÞHðt   TiÞ
  ½ðkgcat=K
g
m;1 þ k
g
inact=K
g
I ÞEg   f
g
u  Cg
 
Vgmax;2
Kgm;2 þ f
g
u  Ch
 f gu  Cg  
Qg
Vg
f gu  Cg
dETot;g
dt
¼ kgdeg  1þ
ðFIgmax   1Þ
ECg
50
þ ðf gu  CgÞ1
tr
nE
 !tr
ðf gu  CgÞ   ETot;g  1þ
1
kgdeg

kginact
KgI
 tr
ðf gu  CgÞ
1þ
1
Kgm;1
þ
1
Kgi
þ
1
KgI
 !tr
ðf gu  CgÞ
0
B
B
B
B
B
@
1
C
C
C
C
C
A
2
6
6
6
6
6
4
3
7
7
7
7
7
5
Eg ¼
ETot;g
1þ
1
Kgm;1
þ
1
Kgi
þ
1
KgI
 !tr
ðf gu  CgÞ
ð18Þ
8
>
>
>
>
>
>
>
>
>
>
>
>
>
>
><
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>:
where Cg is the concentration of drugs in the gut wall, Fa the fraction absorbed of the drugs,
Di the dose at time Ti, ka the absorption rate constant of the drugs, nDose the total number of
doses given, f gu the fraction of unbound drugs in the gut wall, Vg the volume of the gut wall,
H the Heaviside function and Eg and ETot;g are the free and total normalized enzyme levels to
the initial and basal enzyme level in the gut wall; E0,g. Qg is a hybrid parameter introduced by
Yang [17], which takes into account the membrane permeability of the drugs and blood flow
from the enterocytes to the portal vein (see S3 Appendix for more details). All other parame-
ters, except Vgmax;2 and E0,g, are taken equal to the corresponding liver values.
The concentration within the portal vein sub-compartment is given by:
dCpv
dt
¼
Qpv
Vpv
CAB   Cpv
 
þ
Qg
Vpv
 f gu  Cg ð19Þ
where Cpv is the concentration in the portal vein, Qpv the blood flow of the portal vein and
Vpv the volume of the portal vein.
• Liver Compartment:
Finally the liver compartment is described by the liver model previously described with the
boundary condition C0ðtÞ ¼
QhaCABðtÞ þ QpvCpvðtÞ
Qha þ Qpv
at x = 0 (Eq (6)). All volumes and
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blood flows used for the simulation are taken as the average value of a 70 kg man and are
summarized in S1 Table
Numerical resolution
To resolve the herein PBPK, a program was written in MATLAB1 R2015b [18], using an object-
oriented programming (OOP) approach. First, each compartment was identified as a generic
object which generates a function fi such as
dYi
dt
¼ f t;Yið Þ where fi and Yi are both column
vectors and represent the dynamics of the system and variables of interest (e.g. blood concen-
tration and enzyme level) of the compartment i, respectively. Then, the compartments are
combined in a larger object that connects them with their respective blood flows; used to iden-
tify the source term for each compartment, and generate a generic function f(t, Y) such as
dY
dt
¼ f t;Yð Þ where f tr ¼ ðf tr
1
; f tr
2
; . . . ; f trn Þ and Y
tr ¼ ðY tr
1
;Y tr
2
; . . . ;Y trn Þ. Finally, Y is resolved
by using the solver ode15s, which was the preferred solver as it can solve stiff problems and
adapt the time step for optimum resolution. A more detailed description of the main architec-
ture of the program can be found in the appendix S6 Appendix and the code with an example
in appendix S1 Code.
Parameters
Clinical studies. Ten clinical studies, summarized in Table 2, were selected to assess the
predictions from the PBPK model with the observations. For each clinical study, midazolam
was used to probe the impact of the perpetrator drug on the CYP3A4 enzyme.
Fig 4. The gut-compartmental model. The gut compartment is composed of two sub-compartments; the gut wall and the portal vein sub-
compartments. After an oral administration of a given drug, a fraction Fa is absorbed from the intestine to the gut wall with an absorption rate
constant ka. Once the drug is in the gut wall, it may be metabolized and will cross the cell membrane (passively or actively) at a flow Qg,
depending on drug permeability and villous blood flow (see S3 Appendix), to join the blood circulatory system. Once the drug is in the blood,
it goes to the liver through the portal vein.
https://doi.org/10.1371/journal.pone.0183794.g004
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CYP3A4 enzyme. The CYP3A4 enzyme was the enzyme of interest, as it is the main
enzyme to metabolize midazolam. The amount of the CYP3A4 enzyme in the liver and intes-
tine was taken as equal to 9.228 μmol [8] and 0.070 μmol [8], respectively. To estimate the con-
centrations E0 and E
g
0 for CYP3A4, the respective amounts were divided by the total volume of
hepatocytes Vh, estimated from the liver model, and the gut wall volume given in S1 Table.
The degradation rate constants kdeg and k
g
deg for CYP3A4 were taken equal to 0.0192 h
−1 [29]
and 0.0288 h−1 [29] for the liver and intestine, respectively.
Hepatic clearance. In the PBPK model, three parameters, kcat, Vmax,2 and V
g
max;2, were
introduced. The hepatic blood clearance CLH can easily be obtained from clinical studies,
which represents the clearance due to drug metabolism in the liver with respect to the blood
compartment. Therefore, CLH was corrected to estimate the three parameters. This is done
first by estimating the apparent intrinsic clearance CLint assuming a parallel tube model [9],
due to the similarity with the herein liver model. Then to correct the impact due to exchange
mechanisms between blood and hepatocytes, the metabolic intrinsic clearance CLint [30] was
calculated. The equations for CLint and CLint are:
CLint ¼  
QLiver
f bu
ln 1  
CLH
QLiver
 
CLint ¼
SexðP þ routÞCLint
SexðP þ rinÞ   CLint
8
>
><
>
>:
ð20Þ
where f bu and Sex are the blood fraction unbound and the total exchange surface between blood
and hepatocytes given by the liver model, respectively. Finally, kcat, Vmax,2 and V
g
max;2 can be
Table 2. Summary of 10 in vivo clinical studies used in comparison to the simulations.
Perpetrator Dosage Regimen (p.o) Victim Dosage Regimen (p.o) Observation Ref.
Dose Numbers Interval Dose Intake Time Ratio
(mg) (mg) (h) AUC a Cmax b
Azithromycin 500 3 doses q.d.c Midazolam 15 49.5 1.27 1.29 [19]
Cimetidine 400 3 doses Irregulard Midazolam 15 25 1.35 1.26 [20]
Clarithromycin 500 13 doses b.i.d.e Midazolam 8 144 8.39 3.80 [21]
Diltiazem 60 5 doses t.i.d.f Midazolam 15 25 3.75 2.05 [22]
Ethinyl Estradiol 0.03 10 doses q.d. Midazolam 7.5 217 1.20 1.16 [23]
Fluconazole 400 1 doses q.d. Midazolam 7.5 2 3.50 2.50 [24]
Fluoxetine 60 & 20 5 & 7 doses q.d. Midazolam 10 265 0.84 1.11 [25]
Ketoconazole 400 4 doses q.d. Midazolam 7.5 73 15.90 4.09 [26]
Pleconaril 400 15 doses t.i.d. Midazolam 5 112 0.65 0.76 [27]
Rifampin 600 10 doses q.d. Midazolam 5.5 Multipleg 0.12 0.17 [28]
aAUC: Area Under the Curve AUC ¼
Rþ1
0
CðtÞdt
bMaximum Concentration: Cmax ¼ max
t0
CðtÞ
cq.d.: quaque die (once a day)
dIntakes at 0, 12 and 24.5 h.
eb.i.d.: bis in die (twice a day)
ft.i.d.: ter in die (three times a day)
gIntakes at 118 and 190 h.
https://doi.org/10.1371/journal.pone.0183794.t002
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calculated by:
kcat ¼ fm;3A4 
CLintKm;1
E0Vh
Vmax;2 ¼ ð1   fm:3A4Þ 
CLintKm;2
Vh
Vgmax;2 ¼
ð1   f g3A4ÞA
g
CYPVGW
ð1   f3A4ÞACYPVh
Vmax;2
8
>
>
>
>
<
>
>
>
>
:
ð21Þ
where fm, 3A4 is the fraction metabolized by the CYP3A4 enzyme, ACYP and A
g
CYP are the total
amount of CYP in the liver and intestine, respectively, and f3A4 and f
g
3A4 are the fraction
amount of CYP3A4 in the liver and intestine, respectively. Hepatic and intrinsic clearances
CLH/CLint/CLint and fraction metabolized fm, 3A4 are reported in Table 3, blood fraction
unbound f bu in Table 4, and fraction amounts f3A4/f
g
3A4 and CYP amounts ACYP/ A
g
CYP in
Table S2 Table.
Renal clearance. The renal clearance values CLR were obtained from the literature
(Table 3). As the renal clearance is expressed with respect to the blood compartment, as it is
the case for hepatic clearance, an intrinsic renal clearance CLint,R was calculated by assuming a
well-stirred model [9]. The intrinsic renal clearance CLint,R can be expressed as:
CLint;R ¼
RBP
Kp;K

QKCLR
QK   CLR
ð22Þ
where QK, RBP and Kp,K are the kidney blood flow (S1 Table), the blood-to-plasma ratio
(Table 4) and the kidney partition coefficient (Table 5), respectively.
Remaining parameters. The partition coefficients for each compartment and drug are
found in Table 5. Parameters related to reversible inhibition, MBI and induction are reported
Table 3. Metabolism parameters of the drugs.
Drug CLH CLm, int CLm;int Km fm, 3A4 CLR
L/h L/h L/h μM L/h
Midazolam 34.42 [31] 1095.19 1991.20 2.30 [32] 0.96 [33] 0.09 [5]
Azithromycin 33.60a 353.81 392.18 150.00 [29] 1.00b 9.29a
Cimetidine 13.44 [34] 16.22 16.83 10.00c 0.00 17.22a
Clarithromycin 26.52 [31] 112.47 131.30 50.00d 0.80 6.00 [31]
Diltiazem 50.20a,e 340.21 375.54 30.00d 1.00 [35] 2.88a
Ethinyl Estradiol 42.52a 1643.00 5334.34 18.00d 0.60 [36] 0.00
Fluconazole 0.71 [37],e 0.80 0.80 10.00c 0.00 1.03a
Fluoxetine 40.32 [38] 1083.31 1546.61 10.00c 0.00 0.00
Ketoconazole 0.69 50.74 [4] 51.46 1.52 [4] 0.00 0.00
Pleconaril 24.29 [39] 1953.50 4248.41 10.00c 0.00 0.00
Rifampin 8.66a 50.45 51.17 10.00c 0.00 1.68a
aAverage value from PharmapPendium® database: www.pharmapendium.com
bDrugBank.
cAssumed.
dAssumed to be Equal to Ki when fm, 3A4 is not equal to 0.
eThe Hepatic Clearance was estimated by: CLH = CLT − CLR
https://doi.org/10.1371/journal.pone.0183794.t003
A quantitative systems pharmacology model to predict pharmacokinetic drug-drug interactions
PLOS ONE | https://doi.org/10.1371/journal.pone.0183794 September 14, 2017 15 / 28
in Table 6 for each drug, whereas fraction absorbed Fa, absorption constant rate ka, the hybrid
gut wall flow Qg, and the permeability P for each drug are shown in Table 7. Finally, it is
assumed that there is no active hepatocyte uptake or efflux for all drugs considered in this pres-
ent work (i.e.ρin = 0 and ρout = 0).
Table 5. Tissue-to-plasma partition coefficients of the drugs.
Drug Kp, RBCa Kp, RBb Kp, Kidney Kp, Lungs Kp, Liver Kp, Gut
Midazolam 0.005c 0.84 [44] 1.41 [44] 1.61 [44] 1.31 [44] 1.40 [44]
Azithromycin 12.424c 77.34c 110.75c 23.16c 226.15c 126.72c
Cimetidine 0.657c 0.74c 0.88c 0.89c 0.88c 0.83c
Clarithromycin 0.252c 1.51c 1.02c 0.43c 1.24c 1.83c
Diltiazem 0.816c 5.39c 6.26c 1.49c 11.76c 8.10c
Ethinyl Estradiol 0.632c 10.93c 6.11c 1.38c 7.73c 12.79c
Fluconazole 0.467c 0.54c 0.65c 0.63c 0.66c 0.68c
Fluoxetine 1.000c 6.31c 8.96c 1.87c 18.28c 10.30c
Ketoconazole 0.096c 1.75c 1.01c 0.39c 1.20c 2.00c
Pleconaril 0.258c 4.65c 2.58c 0.69c 3.22c 5.34c
Rifampin 0.074c 0.46c 0.32c 0.29c 0.31c 0.49c
aRBC: Red Blood Cells.
bEstimated by averaging the partition coefficients of the remaining tissues: Kp;RB ¼
Xn
i¼1
ViKp;i=
Xn
i¼1
Vi(see S5 Appendix for equation development).
cTheoretical values estimated using the equations by Rodgers and Rowland. Two formula were used; one for the moderate to strong bases (pKa > 7) and
the group 1 zwitterions (pKa,1 > 7) (Rodgers et al. 2005) and the second for acids, neutrals, weak bases (pKa < 7) and group 2 zwitterions (pKa,1 < 7)
(Rodgers et al. 2006). The parameters used in these equations are given in S3 and S4 Tables.
https://doi.org/10.1371/journal.pone.0183794.t005
Table 4. Fraction unbound and blood-to-plasma ratio of the drugs.
Drug fpu fbu RBP fhu a fgwu a
Midazolam 0.0264 0.0400 [34] 0.66 [31] 0.0202 0.0189
Azithromycin 0.7000 [40] 0.1200 [41] 5.83b 0.0031 0.0055
Cimetidine 0.8730 0.9000 [34] 0.97 [42] 0.9880 1.0000
Clarithromycin 0.1800 [31] 0.2813 0.64 [42] 0.0122 0.0984
Diltiazem 0.2028 0.2200 [34] 0.92 [43] 0.0173 0.0251
Ethinyl Estradiol 0.0300c 0.0355 0.84b 0.0039 0.0023
Fluconazole 0.6893 0.8900 [41] 0.77b 0.1051 1.0000
Fluoxetine 0.0500 0.0500 [41] 1.00d 0.0057 0.0049
Ketoconazole 0.0095 [43] 0.0136 0.70 [43] 0.0075 0.0048
Pleconaril 0.0100c 0.0146 0.69b 0.0041 0.0019
Rifampin 0.1100c 0.1809 0.61b 0.3513 0.2234
afhu ¼
fpu
Kp;Liver
and fgwu ¼
fpu
Kp;Kidney
bRBP = h × Kp, RBC + 1 − h where h = VRBC /VBlood is the hematocrit coefficient.
cDrugBank database: www.drugbank.ca
dAssumed.
https://doi.org/10.1371/journal.pone.0183794.t004
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Table 6. Interaction parameters of the drugs.
Drug Inhibition MBI Induction
Ki kinact KI FImax EC50 EC50a
μM h−1 μM μM μM
Azithromycin 150.00 [29] 0.30 [7] 19.00 [7] 1b +1b +1
Cimetidine 115.00 [29] 0b +1b 1b +1b +1
Clarithromycin 50.00 [29] 3.18 [29] 18.90 [29] 1b +1b +1
Diltiazem 30.00 [29] 1.68 [29] 1.15 [29] 1b +1b +1
Ethinyl Estradiol 18.00 [7] 2.40 [7] 18.00 [7] 70.00 [7] 20.00 [7] 3.33
Fluconazole 3.40 [29] 0b +1b 1b +1b +1
Fluoxetine 8.00 [29] [29] 0.61 [29] 3.10 [29] 0.54 [29] 0.18
Ketoconazole 0.006 [29] 0b +1b 1b +1b +1
Pleconaril +1 0b +1b 34.00 [45] 16.40 [45] 3.83
Rifampin 100.00 [29] 0b +1b 34.00 [29] 0.57 [29] 0.54
aEC50 was corrected to take into account fraction unbound in incubation, permeability and active transport where: EC50 ¼ fu;inc
SexðPþ rinÞ
SexðPþ routÞ þCL

int
 EC50,
Sex = 10046 dm2 is given by the liver model and fu, inc is calculated theoretically by using the formula by Kilford et al. 2008.
bNot known as being a reversible inhibitor, MBI inhibitor or inducer. If not a reversible inhibitor Ki = +1, if not a MBI inhibitor kinact = 0 and KI = +1 and if not
an inducer FImax = 1 and EC50 = +1.
https://doi.org/10.1371/journal.pone.0183794.t006
Table 7. Fraction absorbed, absorption constant rate, Qg and permeability of drug chemicals.
Drug Fa ka Qga P
h−1 L/h μm/h
Midazolam 1.00b 1.16 [31] 15.44 24228.0 [15]
Azithromycin 0.86 [31] 0.11 [31] 20.51 36000.0b
Cimetidine 1.00b 1.00b 2.57 4468.6 [46]
Clarithromycin 0.55 [47] 1.08 [31] 4.77 7807.8 [48]
Diltiazem 1.00 [8] 1.60 [8] 18.41 36000.0b
Ethinyl Estradiol 1.00b 1.00b 15.13 23635.9 [36]
Fluconazole 0.86 [37] 0.88 [37] 6.23 13646.5 [46]
Fluoxetine 1.00b 1.00b 22.29 36000.0b
Ketoconazole 1.00b 1.00b 23.34 36000.0b
Pleconaril 0.70c 1.00b 23.31 36000.0b
Rifampin 1.00b 1.00b 19.18 36000.0b
aQg ¼
CLperm
Qv
fbu
CLpermþ
Qv
fbu
: see S3 and S4 Appendices for more details.
bAssumed.
cDrugBank database: www.drugbank.ca
https://doi.org/10.1371/journal.pone.0183794.t007
Table 8. Sinusoids length for each level.
Level Length
μm
1 344.8
2 185.3
3 92.5
4 46.0
5 22.5
Total 691.1
https://doi.org/10.1371/journal.pone.0183794.t008
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Fig 5. Properties of 5 sinusoid levels from the lobule model. (A) The radius of the sinusoids is expressed as a function of the distance to
the periphery of the lobule. For a given level, the radius is decreasing as the sinusoids are converging toward the center of the lobule. Once
the sinusoids reach their minimum size they merge together which increases the radius size in a stepwise manner. (B) The flow of the
sinusoids is expressed as a function of the distance to the periphery of the lobule. For a given level, the flow is constant, but double when two
sinusoids merge. (C) The velocity of the sinusoids is expressed as a function of the distance to the periphery of the lobule. For a given level,
the velocity is increasing as the sinusoid radius is decreasing. Once the sinusoids reach their minimum size they merge which decreases the
blood velocity suddenly.
https://doi.org/10.1371/journal.pone.0183794.g005
Fig 6. Simulated PK of the perpetrator (blue) and victim (orange) drugs. The simulation were run using the clinical dose regimens from
Table 2: (A) Azithromycin (B) Cimetidine (C) Ethinyl Estradiol (D) Rifampin.
https://doi.org/10.1371/journal.pone.0183794.g006
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Results
Algorithm construction of liver
The algorithm to construct the lobule geometry generated 5 sinusoidal levels, where the length
of each level is represented in Table 8. The volume of one lobule and the number of lobules,
estimated from the parameters in Table 1, are respectively 4.06 × 107 μm3 and 4.16 × 107.
Given the average liver volume of 1.69 L for a man of 70 kg (S1 Table), the construction of
the lobules respecting the algorithm presented in Fig 1C gave a total hepatocytes volume
Vh = 1392 mL and blood volume Vb = 283 mL. Therefore the liver volume given by the model
is 1.67 L, which is slightly less than the input volume. Similarly the blood content can be com-
pared to the literature which varies between 250 mL and 312 mL [49]. Furthermore, the sur-
face exchange between blood and hepatocytes Sex given by the model was estimated to be
Fig 7. Simulated enzyme levels as a function of time. The total enzyne level (free enzyne + enzyme-substrate complex) is represented
as a fold change compared to the initial level. The color gradient indicates the positions within the lobule from blue (Entrance of the lobule) to
red (Exit of the lobule): (A) Azithromycin (MBI inducer) (B) Cimetidine (Reversible inhibitor: No effect on enzyme level) (C) Ethinyl Estradiol
(MBI inhibitor and inducer: It seems that in this case the effect cancels each other out) (D) Rifampin (Inducer).
https://doi.org/10.1371/journal.pone.0183794.g007
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10046 dm2, which is expected to influence the calculation of CLint from in vivo data. Finally,
assuming a cell volume of Vcell = 4 μL/106 cells [50], the number of hepatocytes per liver is
348 × 109 cells which is equivalent to 193 × 106 cells/g of liver. This compares well to the litera-
ture values which range from 65 to 185 × 106 cells/g of liver [51].
The mathematical construction of the lobule gives the radius of the sinusoids for each level
as represented in Fig 5A. Given the number of lobules and the blood flow in the liver, the
blood flow for each sinusoid level can be estimated by dividing the total blood flow by the total
number of sinusoids at a given level as represented in Fig 5B. From the liver blood flow and
the radius of the sinusoids, the velocity in the sinusoids (Fig 5C) was calculated as the ratio of
the sinusoids flow to the cross section area as follows: v(x) = Q(x)/S(s), where the cross section
area of the sinusoids is expressed as S(x) = R(x) (eL − 2RH) (see S1 Appendix).
Simulations and comparisons
The clinical data presented in Table 2 were simulated and the PK profiles of the victim and
perpetrator drugs are represented in Fig 6. In addition to the PK profiles, the model simulates
Fig 8. Simulated PK profile for midazolam after an oral dose of 15 mg and comparison to clinical data. (?) Fee et al. 1987 [20] (•)
Zimmermann et al. 1996 [19].
https://doi.org/10.1371/journal.pone.0183794.g008
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the enzyme level in the liver and gut wall as a result of the different mechanisms involved in
drug metabolism. The enzyme levels as a function of time in the liver are given in Fig 7, where
the spatial effect is also represented with a color gradient. Furthermore, the PK profile of mida-
zolam alone was simulated and compared to clinical data in Fig 8. The model seems to ade-
quately predict midazolam PK. Finally, the PK profiles of midazolam with a placebo and the
perpetrator for each of the clinical studies in Table 2 are represented in Fig 9 and a comparison
of the prediction and clinical observation of the AUCratio and Cmax,ratio are summarized in
Table 9. Fold error in eight out of ten predictions are within 2-fold which is a common criteria
for good prediction [29, 52]. In Fig 10 the observed AUCratio are plotted against the predicted
AUCratio. Most of the predictions are relatively well aligned with the line of unity except for the
pleconaril scenario where the induction was overpredicted, therefore AUCratio underpredicted.
An R2 of 0.85 was calculated which indicates a good correlation between the observations and
the model predictions.
Fig 9. Simulated PK profiles for midazolam with a placebo (blue) or a perpetrator (orange) and comparison to clinical data. The
dots represent the clinical observations: (A) Azithromycin [19] (B) Cimetidine [20] (C) Ethinyl Estradiol [23] (D) Rifampin [28].
https://doi.org/10.1371/journal.pone.0183794.g009
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Discussion
The objective of this work was to develop a mathematical model to predict PK drug-drug
interactions in a dynamic manner which may occur in the liver and the intestine. The main
focus was on the liver, as the majority of drug metabolism and therefore DDIs occur in this
organ. However, to incorporate first pass metabolism the intestine was also included. The
main results from this work are; (i) the liver model is capable of describing the geometry of a
lobule in a simple manner; (ii) the liver model can be incorporated into a PBPK model to pre-
dict the PK profile of a drug; (iii) the PBPK model is, so far, capable of predicting the DDIs
when one enzyme is mainly involved in DDIs. The novelty of the model presented in this
work is the description of the lobule/liver geometry in the simplest manner possible to account
for spatial variation in blood flow, concentrations and enzyme level. Furthermore, a cellular
model was included to model drug transport, i.e. permeability, uptake and efflux, between
blood and hepatocytes and drug metabolism within the hepatocytes, without creating a discon-
tinuity with the historical models (e.g. the well stirred model [9] or parallel tube model [9]). It
has the advantage of comparing the geometrical properties of the lobule generated by the
model to physiological data such as the liver blood content, number of lobules, surface
exchange, sinusoidal radius, velocity, blood flow profile and, the hydrodynamic pressure load.
More detailed geometries have been proposed [14, 53, 54], but their implementation into a
pharmaceutical context is not optimal as it is demanding in computational resources (comput-
ing power and scientific IT support). Therefore it seems that the liver model herein is an
appropriate compromise between the complexity of the model and its implementation. The
calculated blood content in the liver (excluding arteries and veins) is in the range of literature
values which varies between 250 mL and 312 mL [49]. However, the number of cells per gram
of liver is relatively higher than the literature values which range from 65 to 185 × 106 cells/g of
liver [51]. As it was assumed that the hepatocyte plates are homogeneous, the space of Disse
and other cell types (e.g. Kupffer cells) were neglected which could have lead to an overestima-
tion of the number of hepatocytes. Based on the lobule geometry, the surface estimated for
Table 9. DDI prediction for the 10 clinical studies.
Drug AUCratio Cmax, ratio
Perpetrator Victim Observation Prediction F.E.a Observation Prediction F.E.a
Azithromycin Midazolam 1.27 1.16 1.10 1.29 1.08 1.20
Cimetidine Midazolam 1.35 1.32 1.02 1.26 1.20 1.04
Clarithromycin Midazolam 8.39 5.36 1.57 3.80 2.24 1.69
Diltiazem Midazolam 3.75 7.52 2.01 2.05 2.37 1.16
Ethinyl Estradiol Midazolam 1.20 1.00 1.20 1.16 1.00 1.16
Fluconazole Midazolam 3.50 4.85 1.38 2.50 2.15 1.16
Fluoxetine Midazolam 0.84 1.56 1.85 1.11 1.27 1.14
Ketoconazole Midazolam 15.90 18.17 1.14 4.09 3.09 1.33
Pleconaril Midazolam 0.65 0.12 5.30 0.76 0.24 3.17
Rifampin Midazolam 0.12 0.12 1.02 0.17 0.26 1.56
GMFEb 1.52 GMFEb 1.38
aFold Error ¼ 10
log
Ob
Pred








bGMFE: Geomtric Mean Fold Error GMFE ¼ 10
PN
i¼1
log
Obi
Predi








https://doi.org/10.1371/journal.pone.0183794.t009
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exchanges Sex might have been underestimated as it is half of the maximum surface of
exchange; assuming that the surface of all the cells is in contact with blood, which in turn is
expected to influence the calculation of the metabolic intrinsic CLint obtained from in vivo data
for low permeable drugs. A comparison of in vivo and in vitro data across a range of drugs may
allow to estimate a more realistic value of Sex. Finally, the pharmacokinetic profile of midazo-
lam was relatively well predicted as well as the impact of the perpetrator drug on its AUC and
Cmax. Indeed the GMFEAUC was estimated to 1.52 which is in the lower range of literature val-
ues (1.47–2.5 [7, 29]). A comparison to the static combined model by Fahmi et al. [7] and to a
well-stirred model similar to the DDI model by Rowland-Yeo et al. [8] was also made (results
not shown) where the GMFEAUC were estimated at 2.55 and 1.71, respectively, which suggests
that dynamic models are far superior to static models and that geometry might help to
improve predictions. However, it is worth noting that the herein results were estimated with-
out taking into account hepatic uptake, which generally improves predictions [55], and with-
out fitting any parameters. All parameters were taken from the literature or calculated using
published algorithms. Ideally, each parameter should be estimated experimentally in a specific
in vitro assays, where it is assumed that they are representative of what is happening in vivo.
Fig 10. Observed AUCratio versus predicted AUCratio. The solid line represents the line of unity, the dashed lines are the 2-fold errors and
the dotted lines the 5-fold errors.
https://doi.org/10.1371/journal.pone.0183794.g010
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This point needs careful consideration as measuring the drug-metabolizing ability of isolated
hepatocytes leads very often to under-predictions of drug clearance. Moreover, studies have
shown that an oxygen gradient [56, 57] and blood flow [58] (i.e. shear stress) affect the expres-
sion levels of CYPs. The liver model shows that the blood flow inside the liver is non-linear
due to its hierarchical anatomical structure and may explain the notion of zonation, i.e. CYPs
are more highly expressed in certain zones of lobules compared to others. Both effects could be
incorporated into the model, where the oxygen concentration and the variation in shear stress,
related to changes in velocity in a lobule, can be modeled.
Conclusion
A liver model including a simple description of the lobule geometry and the uptake/efflux
transport between the blood and hepatocytes was presented. The model predicts the pharma-
cokinetic profiles, enzyme activity and drug-drug interaction for different type of DDIs. Future
research will test the model with two or more enzymes involved in metabolism to validate the
model further, take into consideration uncompetitive, non-competitive or mixed inhibition
and potentially add a component for the biliary excretion which is not negligible for some
drugs. Furthermore, the model needs to be compared to models with increasing complexity,
i.e. from static models to dynamic model, to assess how the new features of the herein model
improves DDI predictions. Finally, this research focused on the liver as it is the main organ
involved in drug metabolism, but the intestine and kidneys may play a significant role in
DDIs. Therefore combining the herein liver model to a more sophisticated gut model (e.g. the
advanced compartmental absorption and transit (ACAT) model) and/or a kidney model,
where transporters are taking into account, could potentially improve the prediction of DDIs
in the future.
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